Full Press Release Details
Therapeutics Announces $58.88 Million Private Placement in Cash Commitments
by Winklevoss Capital to
a Digital Asset Treasury Strategy
MA - October 6, 2025 - Leap Therapeutics (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology
therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE")
offering led by Winklevoss Capital to initiate a digital asset treasury strategy. Leap has entered into a securities purchase agreement
for the purchase and sale of (i) 95,849,353 shares of common stock (the "Purchased Shares") or pre-funded warrants in lieu
thereof (the "Purchased Pre-Funded Warrants") and (ii) warrants to purchase an additional 71,887,008 shares of common stock
at an exercise price of $0.5335 per share (the "Purchased Warrants" and together with the Purchased Shares and the Purchased
Pre-Funded Warrants, the "Units"), for an aggregate exercise price per Unit of $0.61439.
Capital will provide both capital and strategic support to help Leap structure and execute its digital asset treasury strategy. Leveraging
the expertise of Winklevoss Capital, Leap aims to build long-term shareholder value through active participation in digital assets. A
portion of the capital will be used to continue development of Leap's therapeutic programs, including FL-501 and sirexatamab, which
has recently completed a randomized controlled Phase 2 trial in patients with colorectal cancer that is being presented in a Mini Oral
Session at the European Society for Medical Oncology (ESMO) Congress 2025 on October 19 in Berlin, Germany.
to a lead investor agreement, upon delivery of written notice, Leap will increase the size of its Board of Directors to 12 members
and Winklevoss Capital will have the right to nominate two individuals to Leap's Board of Directors, one of whom shall also be
the chairperson of the Board.
expects to release additional updates regarding its treasury activities in the near-term.
closing of the private placement is expected to occur on or about October 8, 2025, subject to the satisfaction of customary closing
has selected Parcrest as the placement agent.
Lewis & Bockius LLP is acting as legal advisor to Leap.
LLP is acting as legal advisor to Winklevoss Capital.
offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from the registration requirement
of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Section 4(a)(2) of the Securities Act and/or
Regulation D promulgated thereunder, and applicable state securities laws. Accordingly, the securities offered in the private placement
may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption
from the registration requirement of the Securities Act and such applicable state securities laws. Concurrently with the execution of
the securities purchase agreements, the Company and the investors entered into a registration rights agreement pursuant to which the
Company has agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") registering
the resale by the purchasers participating in the offering of the Purchased Shares and the shares of common stock underlying the Purchased
Pre-Funded Warrants and the Purchased Warrants. Any offering of the Company's common stock under the resale registration statement will
only be made by means of a prospectus.
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such state or other jurisdiction. The private placement is being
conducted in accordance with applicable Nasdaq rules and was priced to satisfy the "Minimum Price" requirement (as defined in the
Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab
(DKN-01), a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein and FL-501, a humanized monoclonal antibody targeting
the growth and differentiation factor 15 (GDF-15) protein. For more information about Leap Therapeutics, visit http://www.leaptx.com or
view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.
Capital is an investment firm founded in 2012 by Cameron and Tyler Winklevoss that invests in frontier technologies.
press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section
21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words
such as "anticipate," "expect," "plan," "could," "may," "will,"
"believe," "estimate," "forecast," "goal," "project," and other words of
similar meaning. These forward-looking statements address various matters including statements relating to the anticipated benefits and
timing of the completion of the proposed offering and related transactions, the intended use of proceeds from the offering, the assets
to be held by the Company, the expected future market, price and liquidity of the digital assets the Company acquires, the macro and
political conditions surrounding digital assets, the Company's plan for value creation and strategic advantages, market size and
growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies,
technological and market trends, future financial condition and performance and the expected financial impacts of the proposed transactions
described herein. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause
actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among
others, the risk that the proposed transactions described herein may not be completed in a timely manner or at all; failure to realize
the anticipated benefits of the transactions and the proposed digital asset treasury strategy; changes in business, market, financial,
political and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature
of the price of cryptocurrencies; the risk that the price of the Company's common stock may be highly correlated to the price of
the digital assets that it holds; risks related to increased competition in the industries in which the Company does and will operate;
risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating
to the treatment of crypto assets for U.S. and foreign tax purposes, as well as those risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of
this document, and the Company undertakes no obligation to update or revise any of these statements.
& Chief Executive Officer